Le cluster Prostatic Neoplasms (blood) - Prostatic Neoplasms (surgery)
| 000045 (2005) | John F Ward (États-Unis) ; Judd W Moul | Biochemical recurrence after definitive prostate cancer therapy. Part I: defining and localizing biochemical recurrence of prostate cancer. |
| 000032 (2008) | Bridget F Koontz (États-Unis) ; Vladimir Mouraviev ; Jeffrey L Johnson ; Janice Mayes ; Stephanie H Chen ; Terence Z Wong ; Mitchell S Anscher ; Leon Sun ; Judd Moul ; Thomas J Polascik | Use of local (111)in-capromab pendetide scan results to predict outcome after salvage radiotherapy for prostate cancer. |
| 000046 (2004) | Rodney J Ellis (États-Unis) ; Edward Kim ; Ryan Foor | Role of ProstaScint for brachytherapy in localized prostate adenocarcinoma. |
| 000067 (1998) | P J Bohdiewicz (États-Unis) | Indium-111 satumomab pendetide: the first FDA-approved monoclonal antibody for tumor imaging. |
| 000077 (1996) | D Kotz | Monoclonal antibody scan holds promise for prostate cancer staging. |
| 000041 (2005) | Peter S Conti (États-Unis) ; Christine White ; Peter Pieslor ; Arturo Molina ; Jacqueline Aussie ; Paul Foster | The role of imaging with (111)In-ibritumomab tiuxetan in the ibritumomab tiuxetan (zevalin) regimen: results from a Zevalin Imaging Registry. |
| 000068 (1998) | M J Blend (États-Unis) ; V A Bhadkamkar | Impact of radioimmunoscintigraphy on the management of colorectal and ovarian cancer patients: a retrospective study. |
| 000076 (1996) | G Mardirossian (États-Unis) ; A B Brill ; K M Dwyer ; D Kahn ; W Nelp | Radiation absorbed dose from indium-111-CYT-356. |
| This area was generated with Dilib version V0.5.76. |  |